CA2951578A1 - Ceramides and their use in diagnosing cvd - Google Patents
Ceramides and their use in diagnosing cvd Download PDFInfo
- Publication number
- CA2951578A1 CA2951578A1 CA2951578A CA2951578A CA2951578A1 CA 2951578 A1 CA2951578 A1 CA 2951578A1 CA 2951578 A CA2951578 A CA 2951578A CA 2951578 A CA2951578 A CA 2951578A CA 2951578 A1 CA2951578 A1 CA 2951578A1
- Authority
- CA
- Canada
- Prior art keywords
- ceramide
- cer
- formula
- carbon atoms
- alkyl chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012543P | 2014-06-16 | 2014-06-16 | |
| US62/012,543 | 2014-06-16 | ||
| US14/677,595 US9347960B2 (en) | 2014-06-16 | 2015-04-02 | Ceramides and their use in diagnosing CVD |
| US14/677,595 | 2015-04-02 | ||
| PCT/EP2015/063492 WO2015193325A2 (en) | 2014-06-16 | 2015-06-16 | Ceramides and their use in diagnosing cvd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2951578A1 true CA2951578A1 (en) | 2015-12-23 |
Family
ID=54835950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2951578A Abandoned CA2951578A1 (en) | 2014-06-16 | 2015-06-16 | Ceramides and their use in diagnosing cvd |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US9347960B2 (enExample) |
| EP (2) | EP3155440B1 (enExample) |
| JP (1) | JP6774879B2 (enExample) |
| KR (3) | KR102636885B1 (enExample) |
| CN (1) | CN106461685B (enExample) |
| CA (1) | CA2951578A1 (enExample) |
| MX (1) | MX380642B (enExample) |
| SA (1) | SA516380503B1 (enExample) |
| SG (1) | SG11201609621RA (enExample) |
| WO (1) | WO2015193325A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| US10996231B2 (en) * | 2014-12-16 | 2021-05-04 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| US12313634B2 (en) * | 2017-11-20 | 2025-05-27 | Zora Biosciences Oy | Methods for prediction and early detection of diabetes |
| CN114062581A (zh) * | 2017-12-14 | 2022-02-18 | 江苏豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2020112149A1 (en) * | 2018-12-01 | 2020-06-04 | Binhai Industrial Technology Research Institute Of Zhejiang University | Methods and compositions for the assessment of acute myocardial infarction (ami) |
| SG11202105172PA (en) * | 2018-12-06 | 2021-06-29 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN112730638B (zh) * | 2020-11-25 | 2022-07-29 | 首都医科大学附属北京朝阳医院 | 糖尿病合并心梗代谢标志物、检测试剂及试剂盒 |
| CN112986454A (zh) * | 2021-05-18 | 2021-06-18 | 天津云检医疗器械有限公司 | 急性心肌梗死的血清标志物、试剂盒和用途 |
| CN113495160B (zh) * | 2021-09-07 | 2021-11-19 | 宝枫生物科技（北京）有限公司 | 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用 |
| WO2023108294A1 (en) * | 2021-12-17 | 2023-06-22 | National Research Council Of Canada | Diagnostic lipid biomarkers for covid-19 and methods for use thereof |
| CN116500179B (zh) * | 2023-04-21 | 2023-12-26 | 南京品生医疗科技有限公司 | 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统 |
| CN119198939B (zh) * | 2024-08-30 | 2025-06-03 | 北京大学第三医院（北京大学第三临床医学院） | 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012018771A2 (pt) | 2010-01-29 | 2017-06-20 | Metanomics Gmbh | ''método para dianosticar insuficência cardíaca em um sujeito'' |
| DK2385374T4 (en) * | 2010-05-05 | 2018-04-30 | Zora Biosciences Oy | LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE |
| EP3293522A3 (en) * | 2010-06-20 | 2018-05-02 | Zora Biosciences OY | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP3527990A1 (en) | 2011-07-28 | 2019-08-21 | metanomics GmbH | Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| JP6389184B2 (ja) | 2012-10-18 | 2018-09-12 | メタノミクス ゲーエムベーハー | サンプルにおいて代謝産物疾患バイオマーカーのクリアランス正規化量を決定するための手段及び方法 |
| CN105008931A (zh) | 2013-03-08 | 2015-10-28 | 佐拉生物科学公司 | 非高密度脂蛋白来源的cvd标志物 |
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
-
2015
- 2015-04-02 US US14/677,595 patent/US9347960B2/en active Active
- 2015-06-16 EP EP15733650.4A patent/EP3155440B1/en active Active
- 2015-06-16 CN CN201580031908.1A patent/CN106461685B/zh active Active
- 2015-06-16 KR KR1020177000864A patent/KR102636885B1/ko active Active
- 2015-06-16 CA CA2951578A patent/CA2951578A1/en not_active Abandoned
- 2015-06-16 EP EP22168767.6A patent/EP4089416A1/en active Pending
- 2015-06-16 WO PCT/EP2015/063492 patent/WO2015193325A2/en not_active Ceased
- 2015-06-16 KR KR1020247004744A patent/KR102864779B1/ko active Active
- 2015-06-16 KR KR1020257030977A patent/KR20250139419A/ko active Pending
- 2015-06-16 MX MX2016016742A patent/MX380642B/es unknown
- 2015-06-16 JP JP2016573763A patent/JP6774879B2/ja active Active
- 2015-06-16 SG SG11201609621RA patent/SG11201609621RA/en unknown
-
2016
- 2016-05-19 US US15/159,650 patent/US10197582B2/en active Active
- 2016-12-15 SA SA516380503A patent/SA516380503B1/ar unknown
-
2018
- 2018-12-12 US US16/218,363 patent/US11474116B2/en active Active
-
2022
- 2022-02-10 US US17/668,927 patent/US11940453B2/en active Active
-
2024
- 2024-02-14 US US18/441,255 patent/US20240183866A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106461685A (zh) | 2017-02-22 |
| EP3155440B1 (en) | 2022-04-20 |
| BR112016028534A2 (pt) | 2017-08-22 |
| JP6774879B2 (ja) | 2020-10-28 |
| US20240183866A1 (en) | 2024-06-06 |
| US20160266152A1 (en) | 2016-09-15 |
| KR20240023696A (ko) | 2024-02-22 |
| KR102636885B1 (ko) | 2024-02-19 |
| US9347960B2 (en) | 2016-05-24 |
| WO2015193325A2 (en) | 2015-12-23 |
| US11940453B2 (en) | 2024-03-26 |
| CN106461685B (zh) | 2021-05-25 |
| US20220163547A1 (en) | 2022-05-26 |
| US20150362513A1 (en) | 2015-12-17 |
| KR102864779B1 (ko) | 2025-09-25 |
| MX380642B (es) | 2025-03-12 |
| EP3155440A2 (en) | 2017-04-19 |
| US20190113531A1 (en) | 2019-04-18 |
| SG11201609621RA (en) | 2017-01-27 |
| EP4089416A1 (en) | 2022-11-16 |
| MX2016016742A (es) | 2017-04-27 |
| US11474116B2 (en) | 2022-10-18 |
| SA516380503B1 (ar) | 2023-03-23 |
| WO2015193325A3 (en) | 2016-02-25 |
| KR20170018905A (ko) | 2017-02-20 |
| US10197582B2 (en) | 2019-02-05 |
| JP2017519989A (ja) | 2017-07-20 |
| KR20250139419A (ko) | 2025-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11940453B2 (en) | Ceramides and their use in diagnosing CVD | |
| Afshinnia et al. | Lipidomics and biomarker discovery in kidney disease | |
| Deidda et al. | Metabolomics, a promising approach to translational research in cardiology | |
| EP2504708A1 (en) | Lipid biomarkers for stable and unstable heart disease | |
| CN108711451A (zh) | 建立急性主动脉夹层诊断标准的方法 | |
| Laaksonen | Identifying new risk markers and potential targets for coronary artery disease: the value of the lipidome and metabolome | |
| US20190086386A1 (en) | USE OF CERAMIDES AND LPLs IN DIAGNOSING CVD | |
| JP2025063061A (ja) | 心血管イベントに対するバイオマーカー | |
| HK40083140A (en) | Ceramides and their use in diagnosing cardiovascular diseases | |
| CN114938659B (zh) | 基于代谢组学数据的心血管病发病风险评估标志物及应用 | |
| Ge et al. | Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction | |
| HK1230721A1 (en) | Ceramides and their use in diagnosing cvd | |
| HK1230721B (en) | Ceramides and their use in diagnosing cvd | |
| BR112016028534B1 (pt) | Composição compreendendo ceramidas, kits e métodos in vitro para determinar o risco do desenvolvimento de doenças ou complicações cardiovasculares, avaliar e escolher tratamentos | |
| KR102897948B1 (ko) | 심혈관계 이벤트용 바이오마커 | |
| Grau et al. | Bringing Human Serum Lipidomics | |
| WO2025032173A1 (en) | Biomarkers for metabolic syndrome biomarkers for metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20211123 |
|
| FZDE | Discontinued |
Effective date: 20211123 |